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Abstract
Background: Estrogen receptors alpha and beta (ERα and ERβ) differentially activate genes with
AP-1 elements. ERα activates AP-1 targets via activation functions with estrogens (the AF-
dependent pathway), whereas ERβ, and a short version of ERα (ERα DBD-LBD) activate only with
anti-estrogens (AF-independent pathway). The DNA binding domain (DBD) plays an important
role in both pathways, even though neither pathway requires ERE recognition.
Results: Mutations of a highly conserved DBD lysine (ERα.K206A/G), lead to super-activation of
AP-1 through activation function dependent pathways, up to 200 fold. This super-activity can be
elicited either through ER AFs 1 or 2, or that of a heterologous activation function (VP16). The
homologous substitution in ERβ, K170A, or in ERα DBD-LBD leads to estrogen-dependent AP-1
activation and loss of the usually potent anti-estrogen effects. Each of numerous K206 substitutions
in ERα, except K206R, eliminates anti-estrogen activation and this loss correlates perfectly with a
loss of ability to titrate a repressive function from the RU486 bound progesterone receptor.
Conclusion: We conclude that ER DBDs contain a complex regulatory function that influences
ligand activation profiles at AP-1. This function, which requires the integrity of the conserved lysine,
both allows for activation at AP-1 with anti-estrogens (with ERβ and ERα DBD-LBD), and prevents
ERα from becoming superactive at AP-1 with estrogens. We discuss the possibility that a repressor
interaction with the DBD both mediates the AF-independent pathway and dampens the AF
dependent pathway. Mutations in the conserved lysine might, by this model, disrupt the binding or
function of the repressor.
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Background
Estrogen receptors alpha and beta (ERα and ERβ) classi-
cally activate transcription by binding to cognate estrogen
response elements (EREs). The receptors also activate
expression of target genes through alternate pathways, e.g.
through AP-1 and CRE-like response elements [1,2]. AP-
1/CRE-like elements bind Jun and related transcription
factors but not ERs [2,3]. ER action at these alternate ele-
ments appears increasingly to be important. For example,
ER/AP-1 pathways underlie estrogen activation of colla-
genase, Cyclin D1 and IGF-1genes [1,2,4]. The relative
contributions of classic and alternate pathways to a given
gene response in vivo have not yet been directly explored.
However, there is suggestive evidence that AP-1 alternate
pathways play an important role in estrogen-dependent
proliferation [1,5-7].
There are two distinct ER/AP-1 pathways: one activated by
estrogens, the other activated by anti-estrogens [1,3,8].
The estrogen-activated ERα/AP-1 pathway is mediated by
ERα's two activation functions: the constitutive AF-1 in
the N'terminal domain (NTD), and the estrogen-activated
AF-2 in the C-terminal ligand binding domain (LBD) [8].
The ligand dependent AF-2 is functional in virtually all
cell types but is blocked by anti-estrogens. Cells of
endometrial origin also support strong AF-1 activity at AP-
1 which is allowed by some anti-estrogens most notably
tamoxifen (Tam) but not by raloxifene or ICI 182,780.
These latter two "pure" anti-estrogens do not permit AF-1
activity most likely because they allow for efficient bind-
ing of the corepressor N-CoR [9]. It is inferred therefore,
that when these pure anti-estrogens activate AP-1 medi-
ated transcription (with ERβ or ERα DBD-LBD) they do so
through an AF-independent mechanism possibly one that
involves N-CoR binding since a mutation that eliminates
N-CoR binding eliminates this anti-estrogen activation
[9].
To summarize our previous work, we have identified two
pathways by which the ER can activate transcription at AP-
1 elements, AF dependent and AF independent. Three
classes of ligands can be distinguished since the AP-1 tar-
gets can be activated: (1) By estrogens through an AF-1
and -2 dependent pathway; (2) By Tam through AF-1, and
partly through the AF-independent activity, and (3) By
"pure" anti-estrogens (ICI and Raloxifene) that activate
only through an AF-independent pathway [9]. The latter
pathway is most prominent in the presence of ERβ and
certain ERαNTD-deleted mutants [8].
The mechanisms that underlie the AF-independent activa-
tion have not been elucidated. However, we have sug-
gested that anti-estrogen-ER complexes increase AP-1
activity by functionally inactivating an unidentified co-
repressor normally associated with the AP-1 complex and/
or its chromatin environment [3,8]. The lack of AF
involvement in this pathway leaves open the question as
to which portions of the ER contribute to this mode of
anti-estrogen action through AP-1. Here we present data
that a domain generally not considered to contain tran-
scriptional activation functions, the DNA binding domain
(DBD), plays a critical role in regulating the balance
between different pathways of ER action at AP-1 sites.
We noted that nuclear receptor DBDs contain a highly
conserved lysine (lys) residue at the base of the first zinc
binding motif (Fig. 1A). In the context of the glucocorti-
coid receptor (GR) this residue is required for GR's ability
to inhibit AP-1 mediated transcriptional activation. Its
mutation to gly or ala converts the GR from an inhibitor
to a stimulator of the AP-1 activity in response to agonist
[10,11]. We noted in a preliminary report that the equiv-
alent ERα mutation (ERα.K206A) potentiates estrogen
action at AP-1 sites, and at hybrid AP-1/cAMP response
elements (CREs) in the context of much larger promoter,
Cyclin D1 [2]. Here we report that mutations of this resi-
due show complex effects on the ligand profile of ER
action at AP-1 sites and propose that DBD interacting pro-
teins could regulate the type of ER pathway used at alter-
nate response elements.
Results
ERα.K206A and K206G are superactive at AP-1 sites but 
not at EREs
We first mutated the conserved ERα lysine residue at the
base of the first zinc finger to ala or gly (ERα.K206A or
K206G, Fig. 1A). Introduction of these mutations was
motivated by reports that mutations in the homologous
residue convert rat and human GRs from inhibitors to
activators at AP-1 regulated genes [10,11]. Data in Fig. 1B
confirm that both E2-liganded ERα.K206A and
ERα.G400V.K206A enhance the activity of an AP-1
responsive reporter gene (Coll73-Luc) more efficiently
than their K206 counterparts in HeLa cells. Also apparent
was the inhibitory nature of the anti-estrogen ligands used
in presence of the K206A mutation, vide infra for further
discussion.
ERα.K206A also showed increased activity in the absence
of exogenous ligands. Fully wild type ERα. G400 (ERα
designated as ERα throughout the remainder of the man-
uscript unless otherwise indicated) exhibits variable levels
of constitutive activity in cell culture because of very low
levels of estrogens in serum [12]. This phenomenon prob-
ably accounts for the increased ability of unliganded ERα
bearing the K206A mutation to enhance AP-1 dependent
transcription because a mutation (G400V) that slightly
reduces ERα affinity for ligand [12] abolished the consti-
tutive activity exhibited by the fully wild type receptor,
without affecting overall E2 response (compare ERαG400
 αNuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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ERαK206A and K206G mutations lead to super-stimulation at AP-1 sites through the estrogen pathway Figure 1
ERαK206A and K206G mutations lead to super-stimulation at AP-1 sites through the estrogen pathway. (A) 
Location of K206 at the base of the first zinc binding domain in the ERα DBD. (B) ERαK206A and ERα G400V.K206A ligand 
profiles in HeLa cells. The panel shows results of HeLa cell transfections in which activity of ERα, and ERα G400V with or 
without the K206A mutation, were assessed at the Coll73-Luc reporter (shown in schematic above), in the presence of a range 
of ligands. Note: ERα refers to the fully wild type human estrogen receptor (Fomerly pHEG0). All mutations in this manuscript 
are in this background unless performed in the human ERα that contains a G400V mutation in the ligand binding domain. This 
latter construct is designated ERαG400V (Formerly pHE0). "No ER" indicates cells transfected exactly as in all others in the 
experiment except that an empty expression vector (pSG5) is transfected instead of the same vector containing receptor 
cDNA, as indicated. Vehicle treatments (No H.) are represented by white bars, ICI by light grey bars, Ral by medium grey bars, 
Tam by dark grey bars and E2 by black bars. The figure represents a single representative experiment with standard deviations 
calculated from multiple wells. (C, D) ERα.K206A and ERα.K206G are both superactive at AP-1 sites, but not EREs. (C) The 
panel shows results from a transfection in which activities of ERα with and without the K206A/G mutations were assessed at 
an AP-1 site (Coll73-Luc reporter). (D) Results of a similar transfection in which activities of the same ERs were assessed at an 
ERE (ERE-Luc). The panel represents a single experiment with average results obtained from triplicate wells.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
Page 4 of 14
(page number not for citation purposes)
to ERαG400V with and with out the K206A mutation, Fig.
1B). ERα.K206G also showed marked ability to enhance
AP-1 activity in response to E2 (Fig. 1C). As mentioned
above, the degree of constitutive activity displayed by ERα
is variable as seen by comparing Fig 1C to 1B. However,
regardless of the amount of constitutive activity, treatment
with E2 always increased the estrogen response in the pres-
ence of the ERα.K206. Additionally, it exhibited enhanced
activity at the Cyclin D1 promoter (not shown, [2]). Curi-
ously, of all mutations tested, be they DBD deletions, chi-
meras, or substitution of K206 to other residues, only
K206A/G sustained superactivity at AP-1 (Figs. 1C, 5A and
data not shown). In distinction, at an ERE, estrogen-
bound ERα.K206A and G showed mildly reduced to nor-
mal levels of activity (Fig. 1D). Thus, K206A and K206G
mutations enhance ERα and ERαG400V activity at AP-1
and CRE-like elements but not at EREs.
ERα enhances AP-1 activity in the presence of E2 in a vari-
ety of cell lines ([3] and references therein). ERα also
enhances AP-1 activity in the presence of the partial ago-
nist/antagonist Tam in cell lines that support AF-1 activity
at AP-1 sites [1,7]. Since the K206A mutation enhances
estrogen activity, we determined whether the ERα.K206A
mutation would also amplify Tam action at AP-1. Consist-
ent with our previous results [1], endogenous ERα acti-
vated AP-1 in the presence of both E2 and Tam in Ishikawa
cells (Figs. 2A insert) whereas endogenous ERα activated
the AP-1 responsive reporter only in the presence of E2 in
MCF-7 breast cells, which do not support AF-1 activity at
AP-1 (Fig. 2B, insert). Co-transfection of both cell types
with the K206A mutation amplified these responses. In
Ishikawas the K206A mutation enhanced both Tam and
E2 response, whereas in MCF-7s ERα.K206A primarily
enhanced the E2 response. The MCF-7 cell response is like
that seen in HeLas (Fig. 1B), which also have very little AF-
1 activity. Enhanced tamoxifen response was also sup-
ported by MDA-MB-435 (a breast cell line; Fig. 3A) and
chicken embryo fibroblasts (CEFs; data not shown) both
of which support AF-1 activity. We conclude that the
ERα.K206A mutation amplifies E2 responses at AP-1 sites
and also amplifies the agonist properties of the mixed
agonist/antagonist Tam in cells that support AF-1 activity
at AP-1 sites.
ERα.K206A activity is dependent on linked activation 
functions, either endogenous or exogenous
We next determined whether the increased activity elicited
by the ERα K206A mutation was truly dependent on ER
activation functions. As indicated above, the ERα.K206A
mutation amplifies Tam responses at AP-1 sites in cells
that support AF-1 activity. To further test the dependence
of Tam's effect on AF-1, we evaluated the effect of an ERα
AF-1 truncation (DBD-LBDα.K206A). This mutation
completely abolished Tam response in MDA-MB-453 cells
ERαK206A super-stimulates in cells that contain endogenous  ERs Figure 2
ERαK206A super-stimulates in cells that contain 
endogenous ERs. Both Ishikawa (A) and MCF-7 cells (B) 
were transfected with Coll73-Luc and treated with ligands as 
indicated in Fig. 1B. The insets show the effect of treatment 
with endogenous receptor only. The main graphs show lig-
and effect in the presence of the indicated transfected ERα (5 
µg).Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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(Fig. 3A). The DBD-LBDαK206A also exhibited dimin-
ished E2 response (which in turn, was abolished by muta-
tion of AF-2; not shown). Similar results were also
obtained in Ishikawa, MDA-MB-231 and CEF cells, all
cells known to support AF-1 activity (not shown). Thus,
ERαK206A-dependent Tam effects at AP-1 sites require
AF-1. In these conditions AF-1 contributes to overall level
of E2 activation, as well, perhaps by synergizing with AF-2.
ERαK206A super-stimulation requires activation functions Figure 3
ERαK206A super-stimulation requires activation functions. (A) Truncation of AF-1 abolishes Tam response to 
ERα.K206A at AP-1 sites in MDA-MB-453 cells, which support AF-1 activity. (B) In HeLa cells, mutation of AF-2, also in the 
ERα.K206A background, abrogates K206A activity. Cells were transfected with ERs bearing K206A mutants in the context of 
full-length receptor, or the ERα DBD-LBD truncation lacking the NTD, which contains AF-1. (C) HeLa cells were transfected 
with ERα.DBD-LBD or its K206A equivalent, or a VP16-DBD-LBD fusion or its K206A equivalent. Note that E2, but not Tam, 
responses are amplified by the K206A mutation in the context of the DBD-LBD truncation but E2 and Tam responses are 
amplified by the K206A mutation in the context of the VP16-DBD-LBD fusion. Results of a representative experiment are 
shown.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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As suggested by the data above, the K206A mutation
exerts its effects via both AFs 1 and 2 in the presence of E2
(Figs. 3A). To test for the contribution of AF-2, we used a
double hydrophobic mutation within the ERα LBD C-ter-
minal helix 12 (M543A;L544A) that completely abolishes
ERα AF-2 activity at classical EREs [13]. We performed this
experiment in HeLa cells, which only support minimal
AF-1 activity. This mutation completely abolished
ERα.K206A action at AP-1 sites in HeLa cells (Fig. 3B).
Thus, ERα.K206A enhances AP-1 activity in HeLa cells in
a manner that is completely dependent on AF-2. These
observations indicate that the enhancement of AP-1 activ-
ity by the K206A ERα DBD is dependent on linked activa-
tion functions AF-1 and AF-2.
We then investigated whether the K206A mutation would
amplify the activity of a heterologous activation function.
Substitution of a strong heterologous activation function
for the ERα N-terminus (VP16) failed to enhance Tam
response at AP-1 sites in HeLa cells. In contrast, fusion of
the same activation function to the DBD-LBDαK206A N-
terminus produced robust Tam activation (Fig 3C). Thus,
the VP16 activation function when fused to the ER DBD is
nearly inactive at AP-1unless the DBD carries the K206A
mutation. This observation suggests that the K206A muta-
tion may relieve a repressive function mediated through
the DBD exerted on linked activation functions when ERα
activates at AP-1. This is further explored below.
The conserved lysine is required for AF-independent anti-
estrogen action at AP-1 sites
ERβ enhances AP-1 activity in the presence of anti-estro-
gens, but not estrogens ([5] and Fig. 4A). We have sug-
gested that these effects require ERβ contacts with
corepressors one of which is N-CoR [3,8,9,14]. Since the
ERα and ERβ DBDs are highly conserved, we examined
the effect of mutating the conserved lysine (ERβ.K170) on
ERβ action at AP-1 sites. In marked contrast to wild type
ERβ, the ERβ.K170A eliminated anti-estrogen enhanced
AP-1 activity and strongly enhanced E2 AP-1 activity (Fig.
4A). Thus, the ERβ.K170A mutation completely reverses
the ligand profile of ERβ action at AP-1 sites.
ERα truncations that lack portions of the NTD also show
potent anti-estrogen responses at AP-1 sites [8]. Fig. 4B
shows that in the absence of the NTD, the K206A muta-
tion abolished potent anti-estrogen effects and, as for ERβ
(Fig. 4A), allowed for enhanced activation with E2. Thus,
K > A mutations of the conserved lysine residue at the base
of the first zinc binding motif both enhance E2/AF-
dependent and eliminate anti-estrogen/AF-independent
activity of ER α and β at AP-1.
Most substitutions of the K206 residue abolish anti-
estrogen activation without conferring super-activation at 
AP-1
As noted earlier both K206A and K206G were superactive
at AP-1/CRE targets. We next explored a gamut of substi-
tutions at the K206 residue to see whether they would
behave similarly. Surprisingly, K206A or K206G were the
sole mutations capable of generating superactivity in the
estrogen pathway (Fig. 1B &1C and 5A). All other amino
acid conversions either left the ability of ERα to stimulate
AP-1 activity relatively intact (K206H, F), or blocked ERα
activity (K206P, E, and L; Fig. 5A). These data suggest that
mutations in the ER DBD fall into three classes with
The ERβ.K170A mutation reverses ERβ ligand activation pro- file at AP-1 Figure 4
The ERβ.K170A mutation reverses ERβ ligand activa-
tion profile at AP-1. (A) Results of a HeLa cell transfec-
tion in which activity of ERβ (530 amino acid isoform) and an 
equivalent K170A mutation (shown in schematic at left) are 
compared at an AP-1 responsive reporter (Coll73-Luc). (B) 
Results of a similar HeLa cell transfection in which the full lig-
and activation profile of the ERα DBD-LBD region and its 
K206A equivalent are compared at AP-1 sites.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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respect to their effects on the AF-dependent responses at
AP-1 sites: those that super-stimulate (A, G), those that
permit relatively normal stimulation (H, F) and those that
fail to stimulate (P, E, and L). These findings point to con-
siderable complexity in the DBD's affects on AF-depend-
ent ER activity at AP-1 sites.
In stark contrast to the mixture of phenotypes in the pres-
ence of estrogen, with one exception, all mutations of the
K206 residue eliminated the AF-independent anti-estro-
gen activation (Fig. 5A). The sole exception was K206R,
mutation to a like amino acid, which maintained anti-
estrogen activity (Fig. 5A). In addition to mutations at the
K206 residue, we have observed that other changes in this
domain, such as deletion or point mutation of an individ-
ual zinc finger lead to a similar loss of anti-estrogen acti-
vation without creating super-activity with estrogen (data
not shown). These observations underscore the hypothe-
sis that the two ER/AP-1 pathways, estrogen and anti-
estrogen, are completely distinct.
The effects of K206 substitutions on anti-estrogen activa-
tion at AP-1 sites are not a consequence of decreased ERα
protein levels. Fig. 5B confirms that ERα steady state levels
are reduced by ICI and Ral and increased by Tam. The
K206A mutation did modestly increase full-length ERα
steady state levels in the presence of E2. However, similar
increases were observed with the other ERα mutations
that do not show superactivity at AP-1 sites (such as
ERα.K206H). Lastly, protein levels of the N'terminal
Anti-estrogen stimulation is highly sensitive to mutations at K206 Figure 5
Anti-estrogen stimulation is highly sensitive to mutations at K206. (A) Results of a HeLa cell transfection in which 
the phenotype of ERα and ERα.K206A are compared with other ERα.K206 mutants. Note that ERα.K206A shows superactiv-
ity in the presence of E2 and little or no activity in the presence of anti-estrogens. Other K206 mutations, with the exception of 
K206 mutation to a like amino acid (K206R), convert anti-estrogen stimulation to repression despite the lack of E2-associated 
superactivity. (B) Alterations in ERα steady state levels do not account for altered phenotypes. HeLa cells were transfected 
with 10 µg of each expression vector, induced with appropriate ligands for 24 hrs and processed for Western blotting. The 
panels show individual exposures of autoradiograms of Western blots of HeLa cell extracts transfected with individual ERα 
mutants or DBD-LBD and its K206A equivalent.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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domain (AF-1) deletion mutants with and without the
K206A mutation were virtually indistinguishable (Fig.
5B). Thus, the dramatic loss of ICI and raloxifene
responses exhibited by the DBD-LBDα.K206A mutant
(Fig. 4B) cannot be explained by reduced protein levels
(Fig. 5B). Overall, our results suggest that effects of the
K206A mutation on steady state levels of ERα are unlikely
to explain ERα.K206A behavior at AP-1.
Substitutions at K206 that abolish the AF-independent 
anti-estrogen activation at AP-1, also abolish the ability of 
the anti-estrogen bound ERα to titrate repressors from the 
progesterone receptor
We previously proposed that AF-independent anti-estro-
gen activation at AP-1 sites involves functional inactiva-
tion of corepressors [3,8,9]. ERα-anti-estrogen complexes
can titrate corepressors from another antagonist-bound
steroid receptor, the PR-RU486 complex, and thereby
increase its activity ([9,15] and Fig. 6, insert). We therefore
tested whether the K206A substitutions would affect the
ability of ERα to sequester corepressors from the PR-
RU486 complex. Data in Fig. 6 confirm that ERα-anti-
estrogen complexes derepress the PR-RU486 complex at a
PRE. Strikingly, they further indicate that these effects are
abolished by nearly all K206 substitutions the sole excep-
tion being ERα.K206R. This particular mutation (K > R)
was also the only mutation that preserved activation
through the ERα/AP-1 anti-estrogen pathway (Fig. 5A).
Thus, we conclude that there is a perfect correlation
between the ability of K206 substitutions to eliminate AF-
independent anti-estrogen action at AP-1 and to eliminate
the ability of ERα to titrate repressors from PR.
The K > A similarly affects TR transcriptional activity and 
the ability of the receptor to interact with a repressor
To extend these studies, we examined the effect of a K > A
mutation of the analogous residue in thyroid hormone
receptor-alpha (TRα), which is known to interact strongly
with a co-repressor complex that includes N-CoR or
SMRT. Fig. 7A confirms our previous observation that
unliganded chicken TRα enhances AP-1 activity and that
addition of T3 abolishes unliganded TRα activity and fur-
ther represses AP-1 activity below basal [16]. Introduction
of an alanine substitution at the K206 homologue
(TRα.K72A; Fig. 7A) abolished unliganded TRα activity,
and actually allowed unliganded TRα to suppress AP-1
activity below basal, just as the ERα.K206A mutation
abolished anti-estrogen activation and allowed anti-estro-
gens to suppress AP-1 activity below basal. Thus, the K72A
mutation allows TRα to enhance AP-1 dependent tran-
scription in the presence of T3, just as ERα.K206A allows
ERα to activate AP-1 activity in response to estradiol, and
equivalent K > A mutations allow other nuclear receptors
to enhance AP-1 activity in response to their cognate lig-
ands [10,11,17].
We then explored whether the K72A mutation would also
affect TRα functional interactions with a corepressor com-
plex at the PRE. Fig. 7B shows that unliganded TRα derep-
resess the activity of the PR-RU486 complex, but that TRα-
K72A did not. Moreover, TRα.K72A showed increased
ability to suppress basal transcriptional activity of a
reporter gene that contains a classic thyroid response ele-
ment, which binds the TR (Fig. 7C), an effect known to be
mediated by recruitment of a repressive complex.
Together, our results are consistent with our hypothesis
that the K > A mutation abolishes the ability of nuclear
receptors to functionally eliminate repressive influences
on their ability to mediate transcriptional regulation.
Discussion
ER influences on physiological and pathological processes
depends on regulation of genes through classic EREs and
alternate response elements, such as AP-1/CRE elements,
and the subsequent interplay of their gene products. As
described in the Introduction, it is important to under-
stand how ERs regulate genes with AP-1/CRE elements
K206 mutations abrogate the ability of ERα to titrate a  repressive function from PR Figure 6
K206 mutations abrogate the ability of ERα to titrate 
a repressive function from PR. (Insert) The experimen-
tal system: HeLa cells were co-transfected with a TAT3-Luc 
reporter that contains three progestin response elements 
(PREs), a PR expression vector (5 µg), and a CMV β-galactos-
idase internal control (2 µg). Transfections also included 
ERα, ERα K206 mutants or empty pSG5 vector ("No ER"; 5 
µg each). (Graph) All cells were treated with the PR antago-
nist RU486 (10-6 M), which promotes recruitment of repres-
sive functions to DNA by PR. The repressive functions are 
competed for by the ER-bound anti-estrogens, as indicated. 
The data is expressed as relative luciferase activity, where 
the ratio of luciferase activity to β-galactosidase activity in 
the absence of ER ligand is set to a value of 1.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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because this type of response element appears to activate
growth factor expression (e.g. IGF I, and Cyclin D1), as
well as underlie ERα effects on cell proliferation [7]. ER
action at AP-1 involves two pathways: AF-dependent,
active in the presence of estrogens; and AF-independent,
active with "pure" anti-estrogens such as raloxifene and
ICI, and exhibited prominently by ERβ or ERα truncations
missing the N-terminal domain.
In this study, we examined the role of the DBD in ER
action at AP-1 sites. In particular, we focused on a lysine
residue at the base of the first zinc binding motif, which is
highly conserved throughout the nuclear receptor family.
Mutation of this residue to ala or gly enhances activity
through the ER/AP-1 AF-dependent pathway but elimi-
nates activation through the "pure" anti-estrogen path-
way. This interconversion is most clearly seen in the
TRα.K72 behaves similarly to ERα.K206A Figure 7
TRα.K72 behaves similarly to ERα.K206A. (A) The K72 mutation eliminates unliganded and enhances liganded stimula-
tion by TRα. HeLa cells were transfected as above using TRα and TRα.K72A, and then treated with 100 nM T3. (B) The K72A 
mutation abrogates unliganded TRα's ability to titrate a repressive function. The experiment was performed as in Fig. 6, except 
that cells were transfected with TRα (5 ug) and treated with 100 nM T3 instead of ER and ER ligands, respectively. (C) The 
K72A mutation enhances TRα's ability to inhibit transcription from classic thyroid response elements (TREs). Cells were trans-
fected with 1 ug TRα and 2 ug TRE2-LUC reporter.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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context of either the ERα deleted of its NTD (K206A), or
in the context of ERβ (K170A; Fig. 4). Bjornstrom and
Sjoberg have also studied the role of the ERβ DBD in anti-
estrogen activation at AP-1 and have similarly found that
mutations widely spaced through the DBD eliminate anti-
estrogen activation and confer some activation with estro-
gen. The K170 residue was not tested in that study and no
superactivation was observed [18]. Their observations are
consistent with our model of two exclusive mechanisms at
AP-1 and the role of the DBD in controlling choice
between the mechanisms.
The homologous mutation in TRα (K72A; Fig 7) exerts a
highly similar phenotype to that of ERs α and β. It con-
verts unliganded TRα stimulation at AP-1 to repression of
basal transcription and converts liganded TRα from inhib-
iting AP-1 activity to stimulating it. Thus, the pathways
affected by the ERα.K206A mutation are likely to be uti-
lized by other members of the nuclear receptor super-
family, as well. In addition, the ERα.K206A mutation
amplifies ERα action at AP-1 sites with a ligand profile
that resembles that of endogenous ERα in MCF-7 and
Ishikawa cells (Fig. 2). Taken together these data suggests
that the K206A and G mutations amplify pathways that
are likely to be physiologically relevant across nuclear
receptors.
While it may seem paradoxical that mutation of a single
residue in the DBD could lead to such disparate ligand
effects, super-stimulation in the presence of estrogens and
complete disruption of stimulation in the presence of
anti-estrogens, the findings strongly corroborate our pre-
vious proposal that estrogen and anti-estrogen effects are
mediated by completely distinct (and mutually exclusive)
mechanisms. Consideration of these models suggest a
hypothesis to explain some of the complex behaviors of
our ER DBD mutants. First, we originally suggested that in
the AF-dependent pathway, estrogen-liganded ERα forms
part of an activation complex at the promoter, which
enhances AP-1 activity (Fig. 8 AF-dependent, left). The
super-activity of K206A/G suggests that the full powers of
the ER activation domains at AP-1 sites are restrained by
interaction with the DBD and an as yet unidentified
repressor, or repressive complex. The K206A/G mutations
eliminate this interaction and thus permit superstimula-
tion (Fig 8, AF-dependent, right). Second, we have pro-
posed that AF-independent activity elicited from the wild
type ER at AP-1 results from functional repressor inactiva-
tion, be it titration, sequestration, or another process (Fig
8, AF-independent, Left). Again, introduction of the
K206A mutation abrogates the interaction of ERs with an
as yet unidentified repressor. Therefore, ER is no longer
able to de-repress AP-1 activity. This model of the anti-
estrogen pathway is consistent with the concordance of
results elicited by the behavior of a wide array of point
mutations at this residue at an AP-1 site (Fig. 5A) and the
behavior of the same mutations in the repressor-titration
assay (Fig. 6). Thus, the behavior of the K206A mutation
at the AF-independent pathway can be explained by sug-
gesting that it blocks functional inactivation of a repressor
with an ER. Such a repressor, or repressive complex, need
not be the same in AF-dependent and AF-independent
pathways.
There is precedence for DBD: co-regulator interactions.
Jun dimerization protein 2 binds the PR DBD [19], four
proteins have been found to interact with the AR DBD
[20], proteins have been found that associate with TR and
RXR DBDs [21], and lastly, HET/SAFb associates with the
ER DBD [22]. Perhaps some of these co-regulators, or oth-
ers like them, are involved in ER action at AP-1. Whatever
the co-regulator, the complex range of behaviors of
ERα.K206 mutations suggests that they affect correspond-
ingly complex functions in the DBD. We are trying to
identify the interacting factors, be they repressive or not,
by testing candidate factors, and screening for interacting
proteins using a modified yeast two-hybrid system and
biochemical techniques.
Although the inactivation of a repressive complex or func-
tion that associates with nuclear receptor DBDs is our
working hypothesis, we cannot absolutely rule out that
the mutation could also alter a post-translational modifi-
cation required for agonist or anti-estrogen behavior at an
AP-1 site. One possibility we entertained was that the
K206 lysine was a target for acetylation. However, the
finding that the K206R mutation leaves the anti-estrogen/
AF-independent pathway intact brings acetylation as a
mechanism into doubt. This conclusion is further sup-
ported by the finding that ERα K206 is not acetylated
([23], and W.L. Kraus, personal communication). To date,
we have no information on other post-translational mod-
ifications that might be altered, such as phosphorylation
or ubiquitination. Additionally, we do not yet know if the
K > A conversion alters sub-cellular localization. We have
only begun to determine the effects of the K206A muta-
tion on localization by tagging ERα.K206A with GFP. We
found no gross alteration in ER localization (data not
shown). This question of altered sub-cellular localization,
however, deserves further inquiry.
One wonders which physiologic or pathophysiologic
processes are regulated by this highly conserved lysine. We
have generated transgenic mice that express the K206A
mutant under the regulation of either a keratin or a mouse
mammary tumor virus promoter. Both develop a hyper-
proliferative response in the targeted tissues that over time
correlate with tumor development (Manuscript in prepa-
ration). This is in keeping with previous findings that
genes associated with growth (e.g., IGF-1) andNuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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proliferative regulation (e.g., Cyclin D1) are regulated by
the ER through AP-1 or AP-1 like elements [2,4]. We are
unaware of a naturally occurring germline or somatic
mutations associated with squamous or breast carcino-
mas that involve the homologous, highly conserved
lysine. However, a naturally occurring mutation in the
Vitamin D Receptor (VDR) at this conserved site (K45;
mutated to K45E) has been associated with a hereditary
form of vitamin D resistant rickets [24]. Therefore, even
though we cannot point to this mutation in a given
human breast carcinoma, or growth disorder of squamous
epithelium, data from our transgenic mice and the discov-
ery of a disease associated with the homologous lysine in
a different nuclear receptor (Vitamin D resistant rickets)
underscore the potential importance that this residue
plays in physiologic or pathophysiologic mechanisms. In
fact, we hope that our work spurs a quest for mutations of
this highly conserved lysine in tumors, or other
pathologies.
Conclusions
Our data indicate that the ER DBD acts as a regulatory
switch that dictates the ligand activation profile at AP-1
sites and thereby distinguishes the AF-dependent (estro-
gen) from the AF-independent (anti-estrogen) pathways.
What are the factors that might bind the ER DBD and
influence ER action at AP-1 sites? Data from three experi-
ments described here corroborate our hypothesis that the
factors are part of a repressive complex: 1) The K > A muta-
tion is able to unmask the activity of a heterologous acti-
vation function (VP16; Fig. 3C), 2) Conversion of K206 to
any residue except the like amino acid, arg, eliminates the
AF-independent pathway (Fig. 5A), and 3) the profile of
activity elicited by the same mutations parallels their
behavior in the repressor titration assay (Fig. 6).
Regardless of the actual mechanism, the degree of super-
stimulation elicited by ERα.K206A is unlikely to be
benign in normal growth and development. In fact, data
from our ERα.K206A transgenic mice bear this out (Man-
uscript in preparation). The extraordinary degree of ER-
stimulated AP-1 activity possible likely needs to be
restrained over a wide range of cellular conditions, though
it may be selectively exposed in some. Given the potential
importance of such mechanisms, it is likely that the pro-
teins that mediate these effects will represent valuable tar-
Model of ER action at AP-1 sites Figure 8
Model of ER action at AP-1 sites. The underlying mechanisms of estrogen and anti-estrogen pathways are distinct. In the 
AF-dependent/Estrogen Pathway: the balance of co-activator and co-repressor functions is altered by the introduction of the 
K206A mutation. Loss of ER: repressor interactions lead to unopposed, potent, co-activator stimulation (right). In the AF-inde-
pendent or anti-estrogen pathway, ERs titrate, or functionally inactivate, a repressive function associated with the promoter (left). 
The K206A mutation renders the ER unable to do so. The star represents a mutation at ERα K206: K > A/G in the AF-depend-
ent pathway; or K > any mutation except arg, in the AF-independent pathway.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/2
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gets for drugs designed specifically to dampen ER
stimulated growth. We are presently searching for proteins
that associate with the ER DBD in a manner influenced by
mutations of this highly conserved lysine, in the hopes
that they will direct novel drug development.
Methods
Cell lines and ER ligands
HeLa, Ishikawa, MCF-7, and MDA-MB-453 cells were
grown in Dulbecco's Modified Eagle's/F-12 Coon's modi-
fied medium (Sigma), with 15 mM Hepes, L-glutamine
(0.438 g/liter), NaHCO3 (1.38 g/liter), 10% iron supple-
mented calf serum (Sigma) which we screen for negligible
E2  activity, and penicillin/streptomycin as previously
described [5,8]. E2 was purchased from Sigma (St. Louis,
Mo). ICI 182,780 was a gift from Dr. Alan Wakeling
(Astra/Zeneca, Macclesfieled, UK). Ral was a gift from Dr.
Stefan Nilsson (Karo Bio AB Huddinge, Sweden).
Plasmids
The following expression vectors were previously
described: ERα: G400, the fully wild type and G400V
which contains the indicated G > V conversion in the LBD
of ERα. These vectors have previously been termed HEG0
and HE0 respectively [12,25]; ERα.K206A [2], the ERβ
530 amino acid isoform [8], and PR [26].
ERαG400V.K206A was generated by D. Barry Starr, using
site directed mutagenesis [27]. ERα mAF-2.K206A was
prepared by ligating a BglII fragment from a mutated ver-
sion of pSG5-ERαLBD [28] into BglII digested ERαK206A.
ERα.K206 was mutated to ala in the context of ERαG400V
and ERα DBD-LBD mutations by site directed mutagene-
sis of HE0 using the Stratagene Quickchange  kit.
ERβ.K170A was made similarly. VP16-ER-DBD-LBD and
the K206A equivalent (both in ERα) were generated by
PCR amplification of ERα amino acids 164–595 using
ERα and ERαK206A as templates. The primers were
designed with EcoRI and SalI sites. The amplified cDNA
sequences were digested with these enzymes and ligated
downstream (in frame) of a cDNA encoding the strong
HSV VP16 activation domain in expression vector pVP16
(Clontech). Primer sequences and PCR conditions are
available on request.
Reporter genes Coll73-Luc [1], ERE-Luc [5], and GAL4-
RE5-Luc (GK1) [29] have been previously described. The
PR (and GR) responsive reporter gene TAT3-Luc (3xPRE)
was a gift from K. Yamamoto (UCSF) and is described in
[30].
Transfections
Transfections were performed as described [2,5,8]. Cells
were grown to an approximate density of 5 × 104 cells/cm2
on 10cm diameter tissue culture plates. The cells were
trypsinized and resuspended in a single 0.4-cm gap elec-
troporation cuvette in 0.5 ml electroporation buffer (PBS
supplemented with 10% glucose and 10 µg/ml BioBrene
detergent; Applied Biosystems, Foster City, CA). Transfec-
tions to determine ER affects on AP-1 activity contained 2
µg of Coll73-Luc and actin β-galactosidase reporters and 5
µg ER vector or empty vector controls. Transfections to
determine ER effects on classical response elements con-
tained 2 µg of the appropriate reporter, an actin-β-galac-
tosidase control, and 1 µg ER expression vector.
Transfections to determine ER affects on PR-RU486 com-
plex activity contained 5 µg of TAT3-Luc reporter, 2 µg of
CMV-β-galactosidase and 5 µg each of PR and ER
expression vectors. Transfected cells were resuspended in
standard growth medium and plated on 12-well dishes.
Ligands were then added at the following final concentra-
tions (ICI 10-7 M, Ral 10-7 M, Tam 5 × 10-6 M, E2 10-7 M,
RU486 10-6 M).
Western Blots
10 cm dishes of HeLa cells (transfected with 10 µg ER
expression vector and 2 µg CMV-β-galactosidase to permit
detection of equivalent transfection efficiency) were
treated with ligands for 24 hrs, chilled on ice, washed with
ice-cold PBS, then incubated in lysis buffer (0.2% Triton
X-100, 150 mM NaCl, 50 mM Tris pH 7.8, 1 mM EDTA,
and 1/1000 dilution Novagen protease inhibitor cocktail)
for 10 mins. They were then scraped and centrifuged at
4°C in an Eppendorf bench top centrifuge at maximum
speed for 15 mins. Protein concentration in cell extract
was determined by standard methods. The concentration
of each sample was normalized by addition of cold lysis
buffer to a final value of approximately 5 mg total protein
per ml. 20–30 µg of proteins were separated by SDS-
PAGE. Proteins were transferred to a wet Immuno-Blot
PVDF membrane (Bio-Rad, Hercules CA), overnight at 90
mA, 30 V, using a standard transfer apparatus. The mem-
brane was then incubated in 5% non-fat milk in PBS-T (1
× PBS, 0.1% Tween-20) for 1 hour and washed twice in
PBS-T for 10 minutes at room temperature. The primary
ERα antibody used in this study was HC-20 (Santa Cruz
Biotechnology, Inc.) directed against the ERα C-terminus.
Primary antibody was diluted 1:2000 in PBS-T and incu-
bated with the membrane for 1 hour, followed by PBS-T
washes, 1 × 15 minutes and then 2 × 5 minutes. The
membrane was incubated for 45 minutes with horse-rad-
ish peroxidase conjugated anti-rabbit IgG (Santa Cruz
Biotechnology, Inc.) diluted at 1:2000 in PBS-T, followed
by PBS-T washes (1 × 15 minutes and 4 × 5 minutes). After
the last wash, the membrane was developed with a
standard ECL kit (Amersham-Pharmacia Biotech), cov-
ered with Saran wrap and exposed to X-ray film.
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AF-2 Activation Function 2
AP-1 Activator Protein-1
CEF Chicken Embryo Fibroblasts
CRE cAMP Response Element
DBD DNA binding Domain
ERα Estrogen Receptor-alpha, fully wild type: G400
ERαG400V Estrogen Receptor-alpha with LBD mutation:
G400V
ERβ Estrogen Receptor-beta
ERE Estrogen Response Element
GR Glucocorticoid Receptor
ICI Imperial Chemical Industries #182,780
LBD Ligand Binding Domain
N-CoR Nuclear receptor Corepressor
NTD Amino (N)-terminal domain
PR Progesterone Receptor
PRE Progesterone Response Element
Ral Raloxifene (Evista)
SMRT Silencing mediator of retinoid and thyroid
receptors
Tam Tamoxifen (Nolvadex)
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